BioArctic’s partner Eisai to present update on the development of BAN2401 at Alzheimer’s Association International Conference 2020
Stockholm, July 22, 2020 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the company’s partner Eisai will present the study design of the Phase 3 program AHEAD 3-45 at the Alzheimer’s Association International Conference 2020 (AAIC®) on July 27–31. In the study, the therapeutic effect of drug candidate BAN2401 (an anti-amyloid beta protofibril antibody) on the progression of preclinical, asymptomatic, Alzheimer’s disease will be investigated. Additionally, Eisai will present interim results from the open label extension study of the Phase 2b study with BAN2401 in early